Objective: To assess CD4 þ T-cell responsiveness to IL-7 and IFN-a in HIV-infected patients who experience poor recovery of CD4 þ T-cell counts during therapy (immune failure patients).
Introduction
Up to 30% of HIV-1-infected individuals receiving antiretroviral therapy (ART) fail to recover CD4 þ T cells counts to normal levels despite sustained HIV suppression [1] . Such patients are referred to as immunologic nonresponders or immune failures. Persistently low CD4 þ T-cell counts are associated with increased risk of non-AIDS-related morbidities [2] [3] [4] . One mechanism that may contribute to poor CD4 þ cell count recovery during ART is chronic immune activation as suggested by studies linking immune failure to increased CD4 þ T-cell activation and cycling as well increased plasma markers of inflammation (sCD14 and IL-6) [5] . Furthermore, increased expression of interferon stimulated genes (ISGs) has been observed in T cells from immune failure patients [6] . Although chronic IFN-I expression has been implicated in models of HIV/simian immunodeficiency viruse (SIV) pathogenesis [7] [8] [9] , it is not known whether IFN-I contributes to impaired CD4 þ cell count recovery in treated patients.
Recovery of T cells in lymphopenic conditions is mediated by thymic output and homeostatic proliferation in response to IL-7 [10, 11] . Ligation of the IL-7 receptor, which comprises CD127 and CD132, transmits signals that promote CD4 þ T-cell survival and proliferation [11] [12] [13] . IL-7-induced signal transducer and activator of transcription 5 phosphorylation (P-STAT5) results in the rapid induction of an antiapoptotic protein, bcl-2, and upregulation of IL-2Ra (CD25) [14] . IL-7-induced Akt phosphorylation (P-Akt) is linked to cell cycle progression and T-cell proliferation [15, 16] . Plasma IL-7 levels in immune failure patients are increased when compared with IL-7 levels in patients who recovered CD4 þ T cells [17] . In contrast, the capacity of CD4 þ T cells to respond to IL-7 stimulation as measured by rapid induction of P-STAT5 is diminished in immune failure patients and associated with reduced expression of CD127 [18] . Thus, diminished IL-7 responsiveness may occur in CD4 þ T cells of immune failure patients, impairing recovery.
We consider the possibility that persistent IFN-I expression could contribute to poor IL-7 responsiveness in immune failure patients. We have demonstrated that P-Akt induction is delayed following exposure of peripheral CD4 þ T cells to IL-7 and that IFN-I impairs this signaling activity [19] . Furthermore, IFN-a inhibits CD4 þ T-cell proliferation responses to IL-7 [19, 20] . Thus, it is possible that IFN-a produced in HIV disease diminishes homeostatic proliferation in response to IL-7 and plays a role in poor CD4 þ T-cell recovery.
We compared IL-7 responsiveness in CD4 þ T cells from immune failure, immune success (persons who experience CD4 þ cell count recovery over 500 cells/ml during ART), and healthy control patients. We assessed CD127 protein expression as well as IFN-a mRNA and ISGs [2 0 -5 0 -oligoadenylate synthetase-1 (OAS1) and myxovirus resistance A protein (MxA)] mRNA expression to determine if IFN-I expression and exposure are related to IL-7 responsiveness. In addition, we evaluated the capacity of T cells from immune failure patients to respond to IFN-a stimulation as IFN-I tolerance has been reported in HIV disease [21] . Our results suggest that IFN-a responsiveness is largely maintained, whereas IL-7 responsiveness is impaired in T cells from immune failure patients. Furthermore, our data suggest that IFN-a may play a role in mediating poor IL-7 responsiveness in T cells from immune failure patients.
Methods

Patients
The work was approved by the institutional review board at University Hospitals. After obtaining written informed consent, blood was drawn into heparin tubes. Immune failure patients were selected on the basis of past clinical history of CD4 þ cell counts 350 cells/ml or less with treatment. As participation was based on past medical history, some patients had achieved slightly higher CD4 þ cell counts at the time of blood draw, with no immune failure patients exceeding 378 cells/ml as indicated in Table 1 . All immune success patients had achieved CD4 þ cell counts more than 500 cells/ml leading up to the study. All HIV-infected donors had plasma HIV RNA below detection limits (typically 50 copies/ml) for at least 2 year leading up to the study. Both CD4 þ cell count nadir and median age of the patients, which are recognized risk factors for immune failure, were not different between immune failure and immune success or healthy control (Table 1) .
Peripheral blood mononuclear cell and T-cell isolation
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood by centrifugation over a Ficoll-Hypaque cushion. For T-cell isolation, the pan Tcell isolation kit (Miltenyi) was used resulting in a mean purity of 94%, as assessed by flow cytometric analysis. mRNA analyses RNA was prepared from cell lysates using the RNeasy Plus Mini Kit (Qiagen, Valencia, California, USA). Total RNA was reverse transcribed into cDNA using the QuantiTect Reverse Transcription Kit (Qiagen). Equal quantities of cDNA for each experimental condition were amplified by real-time PCR using iQ SYBR Green Supermix (Bio-Rad, Hercules, California, USA). Primer pairs used for genes encoding for GAPDH, OAS1, and MxA were previously published [21] , including IFN-a [7] . Samples were amplified using a hot start at 95 8C for 3 min, followed by 50 cycles of 10 s at 95 8C, 10 s at 59 8C, and 30 s at 72 8C, and a postamplification melting curve ramping from 65 to 95 8C in increments of 0.5 8C per 5 s. Abundances of transcripts were calculated relative to Gapdh expression using the formula 2 À[Ct(target gene)ÀCt(Gapdh)] .
Stimulation conditions
To assess proliferation, PBMCs were labeled with carboxyfluorescein succinimidyl ester (CFSE; 0.25 mmol/l at 37 8C for 10 min; Molecular Probes Invitrogen, Grand Island, New York, USA). Staining was quenched with fetal bovine serum (FBS) for 5 min on ice, and then cells were washed with Roswell Park Memorial Institute 1640 medium (10% FBS). PBMCs were resuspended in an X-VIVO 15 serum-free medium supplemented with 1% penicillin streptomycin and incubated at a concentration of 1 million cells/ ml AE rIL-7 (Cytheris; 5 ng/ml) AE IFN-a (PBL Assay Science, Piscataway, New Jersey, USA; 500 U/ml).
Flow cytometry
Freshly isolated PBMCs were incubated with fluorochome-labeled monoclonal antibodies for 30 min: anti-CD3 peridinin chorophyll protein (PerCP), anti-CD45RA phycoerythrin-cyanine 7 (PE-Cy7), anti-CD8 allophycocyanin-cyanine (APC-Cy7), anti-CD27 alexafluor-700 (AF-700), anti-CD127 fluorescein isothiocyanate (FITC), anti-CD38 phycoerythrin-cyanine 5 (PE-Cy5) (all from BD Bioscience, San Jose, California, USA), and anti-CD4 pacific blue (Biolegend, San Diego, California, USA). Cells were washed, fixed, and permeabilized with 2Â perm/wash buffer (BD Bioscience) and incubated with anti-Ki-67 APC for 45 min. For proliferation assays, CFSE-stained PBMCs were incubated with antibodies specific for CD3, CD4, and CD45RA following incubation with Live/Dead Fixable Yellow Dead Cell dye (Invitrogen, Grand Island, New York, USA). For apoptosis studies, cells were washed with cold PBS, resuspended in 1Â binding buffer (BD Bioscience), and then incubated with annexin-V PE (BD Bioscience) at room temperature for 15 min. Intracellular detection of P-Akt and P-STAT5 was performed via the BD Phosflow protocol and incubated with the following fluorochome-labeled monoclonal antibodies for 30 min: anti-CD3, anti-CD4, anti-CD45RA, anti-STAT5 [7] (pY649) APC, and anti-Akt (pS473) PE (BD Bioscience). Flow cytometric analyses were performed with FlowJo software (FlowJo LLC, Ashland, Oregon, USA). Doublets, debris, and dead cells were excluded from analyses.
Statistical analyses
Prism 5 software (Graphpad, La Jolla, California, USA) was used to generate figures and perform statistical analyses. Nonparametric tests (Kruskal-Wallis and Dunn's multiple comparison post test) were used to assess differences between immune failure and immune success or healthy control. Wilcoxon signed rank test was used to assess differences in paired data. All the tests were 2-sided with a significance P value cutoff of 0.05.
Results
IL-7-mediated proliferation and induction of CD25 are diminished in CD4 R T cells from immune failure patients
To test IL-7 responsiveness in CD4 þ T cells, PBMCs were stimulated with rIL-7 and proliferation (CFSE dye T-cell responsiveness to IL-7 in HIV disease Nguyen et al. 2035 dilution at day 7), cell signaling (P-STAT5 and P-Akt at day 3), and cell surface induction of CD25 expression (at day 1) were measured in CD4 þ T cells by flow cytometry. Total CD4 þ T cells from immune failure but not immune success patients exhibited diminished proliferation (%CFSE low) in response to rIL-7 compared with cells from healthy control ( Fig. 1a -c). CD4 þ T cells incubated in medium alone had median %CFSE low values of less than 1%, and these median values were not significantly different between the groups (data not shown). Furthermore, CD3 þ CD4 À T cells from immune failure patients also displayed diminished proliferation (% CFSE low) in response to IL-7 stimulation when compared with cells from immune success and healthy control patients and diminished proliferation indices and % divided cells when compared with cells from healthy control (Supplemental Fig. 1 , http://links.lww.com/QAD/A936).
We also assessed proliferation responses among CD4 þ Tcell maturation subsets. Proliferation responses were diminished among the memory (CD45RA À ) CD4 þ T cells, and a similar trend that was not statistically significant was observed in naïve (CD45RA þ ) CD4 þ T cells (P ¼ 0.059) from immune failure compared with cells from controls ( Fig. 1c ). To further understand the proliferation defect in the CD4 þ cell counts, we calculated the average number of divisions per divided cell (proliferation index) and the proportion of precursor cells that divided at least once (% divided). Both indices were diminished in the memory (CD45RA À ) subset of immune failure patients compared with healthy control (Fig. 1d ). The proliferation index and % divided in the total CD4 þ and CD45RA þ subset and were not statistically different between patient groups (data not shown). Consistent with the above findings, absolute numbers of CD4 þ T cells at the end of the cell culture also suggested that T cells from control patients underwent greater expansion in response to IL-7 than cells from immune failure patients (data not shown).
CD4 þ T-cell proliferation in response to IL-7 stimulation is dependent on cell signaling mediated by P-STAT5 and P-Akt [22] . Therefore, we assessed IL-7-induced P-STAT5 and P-Akt following 3 days of stimulation. P-STAT5 and P-Akt levels in CD4 þ and CD4 À T cells following IL-7 stimulation were not different between immune failure and immune success or healthy control patients (Supplemental Fig. 2 , http://links.lww.com/QAD/A936). IL-7-induced P-STAT5 results in upregulation of CD25 expression [14] . We compared IL-7 induced cell surface CD25 expression between immune failure, immune success, and healthy control patients. PBMCs isolated from patients were incubated in the presence or absence of rIL-7 overnight. Surface expression of CD25 was measured by flow cytometry after gating on CD3 þ CD4 þ T cells (Fig. 1e ). CD25 induction in response to IL-7 was diminished in total CD4 þ T cells and naive subset from immune failure patients. Among memory CD4 þ T cells, induction of CD25 expression by IL-7 was reduced in immune failure patients, particularly among the effector memory subset (Fig. 1f ).
CD4 R T cells from immune failure patients exhibit decreased CD127 expression and increased immune activation
To characterize freshly isolated CD4 þ T cells from immune failure patients and investigate underlying mechanisms that may contribute to poor IL-7 responses in immune failure patients, we measured immune activation (CD38 expression), cell cycling (Ki-67 expression), and IL-7 receptor-a (CD127 expression) as well as proportions of maturation subsets among the CD4 þ T cells ( Table 1 and Fig. 2a ). Among the CD4 þ T cells, immune failure patients had decreased proportions of naïve cells but increased proportions of effector memory cells when compared with healthy control patients. CD4 þ T cells from immune failure patients displayed diminished expression of CD127 within memory T-cell subsets as measured by either proportion of CD127 þ cells ( Fig. 2a ) or MFI of CD127 expression (not shown). Compared with immune success patients, immune failure patients had increased proportions of activated memory T cells (Table 1 ). Furthermore, immune failure patients had increased proportions of cycling cells comparing immune failure with healthy control (naïve, central memory, and effector memory) and comparing immune failure with immune success (central memory). These data are consistent with previous observations and suggest that CD4 þ T cells from immune failure patients are activated and cycling and may be less responsive to IL-7 stimulation due to lower CD127 expression [5] .
Interferon-stimulated gene and IFN-a mRNA expression are increased in CD3 R T cells from immune failure patients We have previously reported the inhibitory effect of IFNa on IL-7-induced proliferation [19] . To address the possibility that T cells from immune failure patients were exposed to IFN-I in vivo, we measured ISG expression in T cells from our patients and found that mRNA expression of OAS1 and MxA were increased in CD3 þ T cells from immune failure patients (Fig. 2b) . To determine if T cells could be a source of IFN-I, expression of IFN-a mRNA was also assessed. We found evidence of increased mRNA expression of IFN-a in T cells from immune failure patients (Fig. 2c) .
Diminished IL-7 responsiveness in immune failure patients is related to expression of CD127 and IFN-a CD127 expression is a strong correlate of IL-7 responsiveness (P-STAT5 induction) in cells from immune failure patients [18] . Therefore, we performed correlation analyses between CD127 expression and IL-7
Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. responsiveness (CD25 induction and proliferation responses). We assessed these relationships using all HIV-infected patients to provide greater analytic power and then examined the relationships in immune failure and immune success patients separately. CD25 induction in response to IL-7 directly correlated with CD127 expression in the HIV-infected patients. When assessed in the immune failure or immune success patients independently, the relationships remained positive and trending but not significant (Fig. 3a) . In contrast, proliferation responses to IL-7 stimulation were poorly correlated with CD127 expression (Fig. 3b) suggesting that diminished CD127 expression may not be a key determinant for diminished proliferation responses observed in CD4 þ T cells from immune failure patients. We also considered the possibility that IFN-a or ISG mRNA expression might be related to proliferation responses to IL-7 stimulation. ISG expression did not correlate with either IL-7-induced CD25 expression or proliferation response (data not shown), whereas IFN-a 2038 AIDS 2016, Vol 30 No 13 mRNA expression in total T cells was inversely correlated with proliferation in the HIV-infected patients (Spearman r ¼ À0.6379, P ¼ 0.0033, n ¼ 18). The relationship was not significant although trending in the same direction among immune failure patients (Spearman r ¼ À0.4667,
IFN-a responsiveness is not diminished CD4 R T cells from immune failure patients
Previous studies suggest that exposure to IFN-I in vivo during HIV or SIV infection may lead to tolerance and reduced IFN-I responsiveness [8, 21] . To assess IFN-a responsiveness in CD4 þ T cells, we measured both the rapid induction of P-STAT1 in freshly isolated PBMCs and the capacity of IFN-a to inhibit T-cell proliferation in cells from all patients. We found that IFN-a-induced P-STAT1 levels were not different between the patients (Fig. 4a ). IFN-a significantly inhibited IL-7-induced proliferation in CD4 þ T cells from all patient groups (Fig. 4b) . The magnitude of IFN-a-mediated inhibition of IL-7-induced proliferation was also similar between groups (median % inhibition equal 55, 53, and 51 for immune failure, immune success, and healthy control, respectively). As IFN-Is have also been implicated in the induction of apoptosis in HIV disease [23] , we also assessed cell death by annexin-V binding following IFNa, IL-7, or IL-7 þ IFN-a simulation. Cells incubated in IFN-a alone did not proliferate above background and did not reveal significant differences in cell death between the patient groups (median percentages of CD4 þ T cells that were annexin V-bound was 7.3, 6.1, and 8.1 for immune failure, immune success, and healthy control patient groups, respectively; P ¼ 0.79). Interestingly, when comparing cells incubated with IL-7 to cells incubated with IL-7 þ IFN-a, we found an increase in cell death in the presence of IFN-a among divided (CFSE low) cells but not undivided (CFSE high) cells from immune failure but not immune success or healthy control patients ( Fig. 4c and d) . Subset analyses of CD45RA þ and CD45RA À cells indicated that adding IFN-a to IL-7-treated cells resulted in significant increases in cell death of divided cells within the naive-enriched (CD45RA þ ) T-cell subset of immune failure patients (Supplemental Fig. 3 , http://links.lww. com/QAD/A936). To ascertain if this observation might be explained by increased frequencies of Terminal memory (CD45RA þ CD27 À ) cells within the CD45RA þ T-cell subset of immune failure patients, we performed correlation analyses between cell death and frequencies of Terminal memory T cells within the CD4 þ CD45RA þ subset that had been measured in the freshly isolated PBMC samples. We did not find a significant relationship between these indices in cells from immune failure patients (Spearman r ¼ 0.32, P ¼ 0.37, n ¼ 10), suggesting that Terminal memory T-cell frequencies are not likely to explain the increased susceptibility to IFN-a-mediated cell death in CD45RA þ cells from immune failure patients. Overall, these observations indicate that despite evidence of increased IFN-I exposure in vivo, CD4 þ T cells from immune failure patients maintained sensitivity to IFN-amediated induction of signaling as well as antiproliferative and pro-apoptotic activity. evidence linking the rate of CD4 þ recovery to CD127 polymorphisms [24] . The importance of IL-7 responsiveness is also raised by studies showing that CD4 þ T cells from immune failure patients respond poorly to IL-7 stimulation as measured by rapid induction of P-STAT5 signaling [18] . In addition to diminished IL-7 responsiveness, it is also possible that fibrosis of lymphoid tissues further contributes to poor CD4 þ cell count recovery during ART by limiting access to IL-7 within reticular networks [25] . Thus, both limited access to IL-7 and limited capacity to respond to IL-7 stimulation may contribute to poor CD4 þ cell count recovery in treated HIV.
Discussion
Here, we describe additional impairments in IL-7 responsiveness in CD4 þ T cells from immune failure patients that are characterized by diminished induction of proliferation over a 7-day stimulation and diminished induction of CD25 after overnight stimulation. Similar to the previous reports of diminished P-STAT5 signaling in T cells from immune failure patients [18] , we found a direct relationship between induction of CD25 and levels of CD127 expression among CD4 þ T cells from HIVinfected patients. These data and the observations that there are increased proportion of CD57 þ 'senescent' CD4 þ T cells in immune failure patients [18] point to a mechanism whereby the accumulation of cells poorly equipped to proliferate in response to IL-7 stimulation may contribute to poor CD4 þ recovery in treated HIV disease. Unlike the previously reported observation of a defect in IL-7-induced P-STAT5 in CD4 þ T cells from immune failure patients [18] , we did not find evidence of diminished P-STAT5 signaling in CD4 þ T cells from immune failure patients. This may be related to differences in approach as we assessed P-STAT5 following 3 days of IL-7 stimulation compared with 15 min in the previous work. We examined the later timepoint to allow a comparison between P-STAT5 signaling and Akt signaling since Akt signaling is consistently measurable after 3 days but not after 15 min of IL-7 stimulation [19] . It is possible that early P-STAT5 signaling defects in immune failure are transient, or alternatively, cells that fail to induce P-STAT5 signals early are lost over a few days of culture.
Consistent with previous observations [18] , we found that CD127 expression was diminished in T cells from immune failure patients, and other studies indicate that IL-7 is increased in plasma of immune failure patients [26] . It is possible, therefore, that reduced CD127 expression is a consequence of increased chronic exposure of T cells to high concentrations of IL-7 in vivo leading to IL-7 hyporesponsiveness. Although CD127 expression correlated with CD25 induction mediated by IL-7, it was a poor predictor of T-cell proliferation responses to IL-7 stimulation. This suggests that the mechanism of impaired IL-7-induced proliferation in CD4 þ T cells from immune failure patients is likely to be complex and not simply a reflection of reduced CD127 expression.
We also confirm a previous report that T cells from immune failure patients display increased ISG mRNA expression [6] and add that these cells also express increased IFN-a mRNA. Notably, the analyses of ISGs and IFN-a mRNA were limited to total CD3 þ T cells. Thus, determining the contribution of CD4 þ and CD8 þ T cells as well as the contribution of memory and naïve cell subsets to IFN-a mRNA will be important in future studies. Although T cells are not necessarily recognized as a predominant producer of IFN-I, previous studies in HIVþ patients indicate that various cell types, including T cells, can contribute to IFN-a production [27] . It is possible that a small contaminating population of cells may have accounted for the IFN-a mRNA signal in our assays; however, we did not observe a relationship between the purity of the sample and the expression levels of IFN-a mRNA (not shown). Although limited by a small sample size, the increased IFN-a mRNA signal observed in T cells from immune failure patients and the trending inverse relationship with T-cell proliferation responses to IL-7 leads us to speculate that autocrine IFN-a production could contribute to poor IL-7 responsiveness in T cells from immune failure patients. Interestingly, this relationship may reflect an indirect mechanism because there was no discernible relationship between ISG expression and IL-7-induced proliferation. Further studies will be important to confirm and expand on these observations. Increased levels of ISG and IFN-a mRNA expression in T cells from immune failure patients suggest that IFN-I exposure may be sustained in immune failure. In certain cell types, chronic exposure to IFN-I in vivo can lead to IFN-I tolerance. For example, monocytes from untreated HIV infected but not healthy control patients are refractory to IFN-a2a-mediated induction of OAS and MxA presumably due to chronic IFN-I exposure during HIV infection [21] . Diminished expression of ISGs also has been observed following IFN-a2a prolonged administration in rhesus macaques [8] . Our data suggest that IFN-a responsiveness as measured by P-STAT1 or inhibition of IL-7-induced proliferation was not impaired in CD4 þ T cells from immune failure patients. Furthermore, CD4 þ T cells from immune failure patients that have divided in response to IL-7 appear more susceptible to IFN-a-enhanced cell death, revealing a potential mechanism that could limit homeostatic recovery of CD4 þ T cells in these patients.
